Exploring High Growth Tech Stocks In The US October 2024
In This Article:
The United States market has remained flat over the past week but has shown a significant increase of 39% over the past year, with earnings expected to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with these optimistic earnings forecasts but also demonstrate strong potential for innovation and scalability in a rapidly evolving sector.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 21.08% | 28.73% | ★★★★★★ |
| Sarepta Therapeutics | 23.80% | 44.01% | ★★★★★★ |
| TG Therapeutics | 28.54% | 43.77% | ★★★★★★ |
| Invivyd | 42.91% | 70.39% | ★★★★★★ |
| Ardelyx | 27.19% | 66.44% | ★★★★★★ |
| Amicus Therapeutics | 20.26% | 62.89% | ★★★★★★ |
| AsiaFIN Holdings | 60.53% | 81.55% | ★★★★★★ |
| Travere Therapeutics | 29.24% | 70.77% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
Alvotech
Simply Wall St Growth Rating: ★★★★★☆
Overview: Alvotech, with a market cap of $3.95 billion, operates through its subsidiaries to develop and manufacture biosimilar medicines for patients globally.
Operations: With a focus on biosimilar medicines, Alvotech generates revenue primarily from its biotechnology segment, totaling $308.73 million.
Alvotech's recent FDA approval for SELARSDI and its strategic partnership with Teva highlight its innovative edge in the biosimilar market, projecting a robust entry into competitive territories by Q1 2025. With an expected revenue growth of 35.3% annually, surpassing the US market's 8.9%, and earnings forecast to surge by 101.42% per year, Alvotech is positioning itself as a formidable player despite current unprofitability. These developments not only enhance Alvotech’s portfolio but also promise substantial market penetration supported by advanced manufacturing techniques like the continuous perfusion process used in SELARSDI’s production.
-
Navigate through the intricacies of Alvotech with our comprehensive health report here.
-
Gain insights into Alvotech's historical performance by reviewing our past performance report.
Datadog
Simply Wall St Growth Rating: ★★★★★☆
Overview: Datadog, Inc. provides an observability and security platform for cloud applications worldwide, with a market capitalization of $42.68 billion.
Operations: The company generates revenue primarily from its Information Technology (IT) Infrastructure segment, which amounts to $2.39 billion.
Datadog has demonstrated a robust financial turnaround, with its recent quarter showing a surge in sales to $645.28 million from $509.46 million year-over-year and transitioning from a net loss to a net income of $43.82 million. This growth is underpinned by strategic moves like the Akamai partnership, enhancing security operations through integrated SIEM solutions in cloud environments—an essential feature as cybersecurity threats evolve. Moreover, the appointment of Yanbing Li as Chief Product Officer injects fresh expertise likely to drive further innovation and efficiency in product development at Datadog, positioning it well for sustained growth amidst competitive tech landscapes.